Search

Your search keyword '"Tang, Yi-Da"' showing total 434 results
Start Over Author "Tang, Yi-Da"
434 results on '"Tang, Yi-Da"'

5. The application of large language models in medicine: A scoping review

Author

Meng, Xiangbin, Yan, Xiangyu, Zhang, Kuo, Liu, Da, Cui, Xiaojuan, Yang, Yaodong, Zhang, Muhan, Cao, Chunxia, Wang, Jingjia, Wang, Xuliang, Gao, Jun, Wang, Yuan-Geng-Shuo, Ji, Jia-ming, Qiu, Zifeng, Li, Muzi, Qian, Cheng, Guo, Tianze, Ma, Shuangquan, Wang, Zeying, Guo, Zexuan, Lei, Youlan, Shao, Chunli, Wang, Wenyao, Fan, Haojun, and Tang, Yi-Da

Published
2024
Full Text
View/download PDF

18. Identification of digital twins to guide interpretable AI for diagnosis and prognosis in heart failure.

Author

Gu, Feng, Meyer, Andrew J., Ježek, Filip, Zhang, Shuangdi, Catalan, Tonimarie, Miller, Alexandria, Schenk, Noah A., Sturgess, Victoria E., Uceda, Domingo, Li, Rui, Wittrup, Emily, Hua, Xinwei, Carlson, Brian E., Tang, Yi-Da, Raza, Farhan, Najarian, Kayvan, Hummel, Scott L., and Beard, Daniel A.

Abstract

Heart failure (HF) is a highly heterogeneous condition, and current methods struggle to synthesize extensive clinical data for personalized care. Using data from 343 HF patients, we developed mechanistic computational models of the cardiovascular system to create digital twins. These twins, consisting of optimized measurable and unmeasurable parameters alongside simulations of cardiovascular function, provided comprehensive representations of individual disease states. Unsupervised machine learning applied to digital twin-derived features identified interpretable phenogroups and mechanistic drivers of cardiovascular death risk. Incorporating these features into prognostic AI models improved performance, transferability, and interpretability compared to models using only clinical variables. This framework demonstrates potential to enhance prognosis and guide therapy, paving the way for more precise, individualized HF management. [ABSTRACT FROM AUTHOR]

Published
2025
Full Text
View/download PDF

20. Evaluation of the safety and efficacy of a novel Anatomical classification and dUal anchoRing theory to Optimize the tavR strategy for pure severe Aortic regurgitation (AURORA): a prospective cohort study

Author

Yao, Jing, Lu, Zhi-Nan, Modine, Thomas, Jilaihawi, Hasan, Piazza, Nicolo, Tang, Yi-Da, Xu, Ji-Zhe, Peng, Xiao-Ping, Wang, Hai-Ping, Li, Chuan-Bao, Chen, Hui, Liu, Chang-Fu, Jiang, Zheng-Ming, Li, Jie, Yu, Fei-Cheng, Han, Ke, Wang, Sheng, Huang, Hui, and Song, Guang-Yuan

Published
2022
Full Text
View/download PDF

29. GPR30 Selective Agonist G1 Exhibits Antiobesity Effects and Promotes Insulin Resistance and Gluconeogenesis in Postmenopausal Mice Fed a High‐Fat Diet.

Author

Liu, Da, Zheng, Mingqi, Lu, Congcong, Miao, Mengdan, Zhan, Yinge, Ma, Fangfang, Yin, Yajuan, Wei, Mei, Wang, Wei, Wang, Wenyao, Meng, Xiangbin, Li, Jing, Zhang, Yaohua, Liu, Gang, Tang, Yi-Da, and Lingwood, Clifford A.

Abstract

Background: G1, a specific agonist targeting the G protein–coupled receptor 30 (GPR30), has demonstrated significant involvement in combating obesity and regulating glucose homeostasis. Nevertheless, the beneficial effects of G1 treatment have solely been investigated in animal models under normal feeding conditions, leaving its therapeutic potential in high‐fat feeding scenarios unexplored. Material and Methods: To address this gap, our study employed an ovariectomized high‐fat diet mouse model to assess the therapeutic effects of G1 in combating obesity and metabolic dysfunction. Results: The findings revealed that G1 treatment resulted in weight loss, but concurrently led to increased blood glucose levels and insulin resistance. Treatment with G1 resulted in an amplification of fat mobilization and an enhancement of pyruvate carboxylase activity in mice fed a high‐fat diet. Moreover, the combined impact of G1 treatment and a high‐fat diet on pyruvate metabolism, as well as the regulation of crucial gluconeogenesis enzymes such as pyruvate dehydrogenase kinase 4 (PDK4), phosphoenolpyruvate carboxykinase (PEPCK), and glucose transporter 2 (GLUT2), expedites the elevation of blood glucose and the progression of insulin resistance. Conclusions: These findings indicate that G1 treatment is influenced by a high‐fat diet, potentially disrupting glucolipid metabolism and promoting insulin resistance alongside its antiobesity effects. Consequently, further investigation is imperative to thoroughly explore this potential toxic side effect of G1 therapy. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

37. Evaluating the Efficacy of Transcatheter Edge-to-Edge Repair in Patients with Commissural Degenerative Mitral Regurgitation: A Novel Morphological Classification-Directed Approach

Author

Lu, Zhi-Nan, primary, Guo, Xu-Nan, additional, Ke, Yu-Tong, additional, He, Yihua, additional, Liu, Xianbao, additional, Jiang, Zhengming, additional, Liu, Xinmin, additional, Wu, Wenhui, additional, Tang, Yi-Da, additional, Chai, Dajun, additional, Guo, Yansong, additional, Lam, Yat-Yin, additional, Wu, Yongjian, additional, Piazza, Nicolo, additional, and Song, Guangyuan, additional

Published
2024
Full Text
View/download PDF

44. Changes in Drug Clinical Trials of Thyroid Diseases in China, 2009–2022

Author

Li,Chen, Hao,Jun, Wang,Chuangshi, Yang,Jie, Zheng,Yitian, Zhang,Kuo, Hui,Wen, Meng,Xiangbin, Gao,Jun, Li,Wei, Tang,Yi-Da, Li,Chen, Hao,Jun, Wang,Chuangshi, Yang,Jie, Zheng,Yitian, Zhang,Kuo, Hui,Wen, Meng,Xiangbin, Gao,Jun, Li,Wei, and Tang,Yi-Da

Abstract

Chen Li,1,* Jun Hao,2,* Chuangshi Wang,2 Jie Yang,1 Yitian Zheng,1 Kuo Zhang,3 Wen Hui,4 Xiangbin Meng,1 Jun Gao,1 Wei Li,2 Yi-Da Tang1,5 1Department of Cardiology and Institute of Vascular Medicine, Peking University Third Hospital; Key Laboratory of Molecular Cardiovascular Science, Ministry of Education, Beijing, People’s Republic of China; 2Medical Research and Biometrics Center, National Clinical Research Center for Cardiovascular Diseases, Fuwai Hospital, National Center for Cardiovascular Diseases, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, People’s Republic of China; 3Department of Cardiology, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, People’s Republic of China; 4Department of Science and Technology, West China Hospital, Sichuan University, Chengdu, Sichuan, People’s Republic of China; 5Research Unit of Medical Science Research Management/Basic and Clinical Research of Metabolic Cardiovascular Diseases, Chinese Academy of Medical Sciences, Beijing People’s Republic of China*These authors contributed equally to this workCorrespondence: Wei Li; Yi-Da Tang, Email liwei@mrbc-nccd.com; tangyida@bjmu.edu.cnObjective: The incidence rate of thyroid diseases increased worldwide. This study aims to overview the changing landscape of drug clinical trials on thyroid disease during 2009– 2022.Methods: The detailed information of thyroid disease drug trials registered on the National Medical Products Administration (NMPA) Registration and Information Disclosure Platform for Drug Clinical Studies was searched and collected. The thyroid drug clinical trials were analyzed by the characteristics, time trends, indications, and geographical distribution.Results: Sixty-five thyroid disease drug clinical trials were launched from 2009 to 2022 in China, which include

Published
2023

47. Additional file 5 of Association between liver fibrosis and thrombotic or bleeding events in acute coronary syndrome patients

Author

Liu, Yupeng, Song, Jingjing, Wang, Wenyao, Zhang, Kuo, Yang, Jie, Wen, Jun, Meng, Xiangbin, Gao, Jun, Wang, Jingjia, Shao, Chunli, and Tang, Yi-Da

Abstract

Additional file 5: Supplementary Table 1. Univariable and multivariable Cox regression analysis of MACCE. Supplementary Table 2. Baseline characteristics according to the absence and presence of MACCE

Published
2023
Full Text
View/download PDF

50. Development and validation of a nomogram predicting one-year mortality in patients undergoing percutaneous coronary intervention

Author

SONG, Jing-Jing, LIU, Yu-Peng, WANG, Wen-Yao, YANG, Jie, WEN, Jun, CHEN, Jing, GAO, Jun, SHAO, Chun-Li, and TANG, Yi-Da

Subjects
Research Article
Abstract

OBJECTIVE: To formulate a nomogram to predict the risk of one-year mortality after percutaneous coronary intervention (PCI) based on a large-scale real-world Asian cohort. METHODS: This study cohort included consecutive patients undergoing PCI in the National Center for Cardiovascular Diseases of China. The endpoint was all-cause mortality. Least absolute shrinkage and selection operator Cox regression and backward stepwise regression were used to select potential risk factors. A nomogram based on the predictors was accordingly constructed to predict one-year mortality. The performance of the nomogram was evaluated. Patients were stratified into low-, intermediate- and high-risk groups according to the tertile points in the nomogram and compared by the Kaplan-Meier analysis. RESULTS: A total of 9603 individuals were included in this study and randomly divided into the derivation cohort (60%) and the validation cohort (40%). Six variables were selected to formulate the nomogram, including age, renal insufficiency, cardiac dysfunction, previous cerebrovascular disease, previous PCI, and TIMI 0–1 before PCI. The area under the curve of this nomogram regarding one-year mortality risks were 0.792 and 0.754 in the derivation cohort and validation cohort, respectively. Kaplan-Meier curve successfully stratified the patients according to three risk groups. This nomogram calibrated well and exhibited satisfactory clinical utility in the decision curve analysis. CONCLUSIONS: This study developed and validated a simple-to-use nomogram predicting one-year mortality risk in Asian patients undergoing PCI and could help clinicians make risk-dependent decisions.

Published
2022

Catalog

Books, media, physical & digital resources
See catalog results